Table 1.
Ex vivo expansion of γδ T cells from cancer patient PBMCs with BrHPP
| Day 0–4 | Day 15–17 | ||||
|---|---|---|---|---|---|
| PBMC seeded (×106) | γδ T cells (%) | Cells recovered (×106) | γδ T cells (%) | γδ T cell expansion index | |
| C301 | 1 | 25 | 21 | 92 | 77 |
| C314 | 1 | 1 | 26 | 90 | 2,340 |
| C319 | 2 | 6 | 18 | 70 | 105 |
| C322 | 3 | 5 | 27 | 96 | 173 |
| C335 | 12 | 10 | 293 | 97 | 237 |
| C337 | 6.4 | 4 | 295 | 93 | 1,072 |
| H325 | 3.6 | 2 | 158 | 96 | 2,107 |
| H328 | 1 | 2 | 29 | 83 | 1,204 |
| H329 | 4 | 1 | 44 | 85 | 935 |
| H334 | 11.5 | 9 | 356 | 96 | 330 |
| SA309 | 0.5 | 6 | 15 | 97 | 485 |
| Mean ± SD | 6 ± 7 | 90 ± 8 | 824 ± 798 | ||
Cells are from patients suffering from CRC (C), HCC (H) or sarcoma (SA). The percentage of cells expressing the γδ-TCR was determined by flow cytometric analyses using anti-pan-γδ mAb, at the beginning (day 0–4) and at the end (day 15–17) of the culture. Control cultures without BrHPP contained 10 ± 10% γδ T cells at the same time. γδ T cell expansion index = number of γδ T cells recovered/number of γδ T cells seeded